VEGFA and cancer: We demonstrated that ramucirumab abrogated both VEGF-A- and pediatric cancer cell-driven endothelial cord formation in vitro; furthermore, treatment with DC101 improved response to chemotherapy in several xenograft mouse models representing a range of pediatric tumor types with high unmet need.